Receptor pharmacology of neuroleptics: Relation to clinical effects

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 10, 1999, Pages 5-14

  Richelson, Elliott ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMOXAPINE; ATROPINE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXAZOSIN; DROPERIDOL; FLUPHENAZINE; GUANABENZ; GUANABENZ ACETATE; HALOPERIDOL; LABETALOL; LOXAPINE; LOXAPINE SUCCINATE; METHYLDOPA; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PRAZOSIN; QUETIAPINE; RAUWOLSCINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SERTINDOLE; TERAZOSIN; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; DEPOLARIZATION; DISSOCIATION CONSTANT; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTRIC ACTIVITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSALIVATION; NEUROTOXICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR BINDING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; HUMANS; MUSCARINIC ANTAGONISTS; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032935962     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Driscoll MS, Rothe MJ, Grantkels JM, et al. Delusional parasitosis: a dermatologic, psychiatric, and pharmacologic approach. J Am Acad Dermatol 1993;29:1023-1033
2. i values. J Pharmacol Exp Ther 1989;251:238-246
3. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34
4. Coffey L. Options for the treatment of negative symptoms of schizophrenia. CNS Drugs 1994;1:107-118
5. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
6. 2 receptors. J Pharmacol Exp Ther 1993;266:1374-1384
7. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
8. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 1995;120:365-368
9. t serotonin receptors may reflect psychoactive profile. Mol Med 1995;1:398-406
10. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992; 260:576-580
11. 4 receptor agonist. Eur J Pharmacol 1994;269:R1-R2
12. Zeng XP, Le F, Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997;321:349-354
13. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-1619
14. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221: 1054-1057
15. Deutch AY, Duman RS. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterizatior. Neuroscience 1996;70:377-389
16. Kostowski W, Gurnulka W, Cxlonkowski A. Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 1972;48:443-446
17. Balsara JJ, Jadhav JH. Muley MP, et al. Effect of drugs influencing central 5-hydroxytryptaminergic mechanisms on morphine-induced catalepsy in the rat. J Pharm Pharmacol 1979;31:255-257
18. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
19. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719
20. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984;103: 197-204
21. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992:49:538-544
22. 2 receptor occupancy studies and clinical response. Br J Psychiatry 1996;168(suppl 29):40-44
23. 2 and D-2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997;16:1-7
24. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998;3:135-140
25. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, et al. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 1985;85:329-332
26. 2 receptor blocking agent. Curr Ther Res 1986;40:492-499
27. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995;15:821-829
28. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-1486
29. Devaud LL, Hollingsworth EB, Cooper BR. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin(2) receptor antagonist, ritanserin. J Neurochem 1992;59:1459-1466
30. Duinkerke SJ, Botter PA, Jansen AAI, et al. Ritanserin, a selective 5-HT(2/1c) antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451-455
31. Ohuoha DC, Hyde TM, Kleinman JE. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology 1993; 112:S5-S15
32. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-1529
33. Kapur S, Cho R, Jones C, et al. Is amoxapine an atypical antipsychotic? supportive PET evidence [abstract]. Biol Psychiatry 1998;43:18S
34. Simpson GM, Cooper TB, Lee JH, et al. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology 1978;56: 225-232
35. Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1991;564:213-221
36. Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 1993;31:177-183
37. Hüe B, Palomba B, Giacardy-Paty M, et al. Concurrent high-performance liquid chromatographic measurement of loxapine and amoxapine and of their hydroxylated metabolites in plasma. Ther Drug Monit 1998;20: 335-339
38. Lucas JJ, Hen R. New players in the 5-HT receptor field: genes and knockouts. Trends Pharmacol Sci 1995;16:246-252
39. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410
40. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 1997;54:567-572
41. Sokoloff P, Schwartz JC. Novel dopamine receptors half a decade later. Trends Pharmacol Sci 1995;16:270-275
42. Van Tol HHM, Wu CM, Guan HC, et al. Multiple dopamine-D4 receptor variants in the human population. Nalure 1992;358:149-152
43. Sommer SS, Lind TJ, Heston LL, et al. Dopamine-d(4) receptor variants in unrelated schizophrenic cases and controls. Am J Med Genet 1993;48: 90-93
44. Petronis A, Macciardi F, Athanassiades A, et al. Association study between the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1995; 60:452-455
45. Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-445
46. 125I]epidepride. Eur J Pharmacol 1995;286:R3-R5
47. Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996;219:163-166
48. Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 1974;248:596-597
49. Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974;31:58-61
50. Kubo T, Fukuda K, Mikami A, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986;323:411-416
51. Bonner TI, Buckley NJ, Young AC, et al. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527-532
52. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 1991;192:205-206
53. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2: 281-293
54. Flynn DD, Ferraridileo G, Mash DC, et al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891
55. 2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther 1988;244:987-993
56. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation [letter]. Lancet 1995;346:1034
57. Spivak B, Adlersberg S, Rosen L, et al. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 1997;12:213-215
58. Zeng XP, Le F, Scarisbrick I, et al. Muscarinic m4 receptor agonism by atypical but not typical antipsychotics [abstract]. Soc Neurosci 1995;21: 1707
59. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-294
60. Mereu G, Lilliu V, Vargiu P, et al. Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. Eur J Pharmacol 1994;264:449-453
61. Mereu G, Lilliu V, Vargiu P, et al. Depolarization inactivation of dopamine neurons: an artifact? J Neurosci 1995;15:1144-1149
62. Melis M, Mereu G, Lilliu V, et al. Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats. Brain Res 1998;783:127-132
63. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res 1985;22:196-203
64. Nutt DJ, Lalies MD, Lione LA, et al. Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 1997;11:163-168
65. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? [letter] J Psychopharmacol 1995;9:155
66. Schwartz JC, Arrang JM, Garbarg M, et al. Histamine. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995
67. Hale AS. Olanzapine. Br J Hosp Med 1997;58:442-445
68. Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984;103: 197-204
69. Richelson E, Souder T, Acuna J, et al. Binding studies with some new neuroleptics at human brain receptors [abstract]. Biol Psychiatry 1997;41 (suppl 7):228